Landsberg Bennett & Dubbaneh’s Alexion Pharmaceuticals ALXN Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,285	Closed	-$482K	–	245
2020 Q3	$482K	Buy	4,285 +205	+5%	+$22.1K	0.08%	142
2020 Q2	$454K	Buy	4,080 +662	+19%	+$70.3K	0.09%	149
2020 Q1	$309K	Buy	+3,418	New	+$335K	0.09%	131
2019 Q4	–	Sell	-4,757	Closed	-$465K	–	260
2019 Q3	$465K	Sell	4,757 -299	-6%	-$33.7K	0.13%	145
2019 Q2	$664K	Sell	5,056 -1,357	-21%	-$175K	0.17%	125
2019 Q1	$898K	Buy	+6,413	New	+$797K	0.21%	112

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's ALXN Position: Q4 2020 in Review

Landsberg Bennett & Dubbaneh sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 4,285 shares — an estimated $482K sold.

Landsberg Bennett & Dubbaneh first reported a position in ALXN in Q1 2019 and held it in 6 quarters. The position peaked at $898K in Q1 2019. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Landsberg Bennett & Dubbaneh reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Landsberg Bennett & Dubbaneh sold 4,285 Alexion Pharmaceuticals shares in Q4 2020, an estimated $482K.
Landsberg Bennett & Dubbaneh first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Landsberg Bennett & Dubbaneh's Alexion Pharmaceuticals position peaked at $898K in Q1 2019.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q4 2020, filed 26 Jan 2021.